Glucagon-like peptide-1 receptor (GLP-1R) agonists have garnered significant attention for their therapeutic potential in addressing the interconnected health challenges of diabetes, obesity, and cancer. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.